« Back to List
Southeast Biorepository System Protocol (Two Studies)
Posted by: LMC IRB |
Posted Date: December 14, 2010
About the Southeast Biorepository System
This is the overarching protocol for our tissue banking program. Once this protocol was approved by LMC's IRB, we were able to begin collecting and banking tissue to be held in reserve for future research studies.
After approximately one year of collections, LMC was able to support the opening of its first tissue banking related study.
Title: Approved Study #1: Factors Associated with
Anti-tumor Immunity in Cancer Patients
Approval Date: January 30, 2008
Principal Investigator: Juhua Zhou, Ph.D.
Details: The aim of this study is to better understand how cancer develops and how the body's immune system works to defeat tumor cells.
The results of this study will provide valuable clues in improving the efficacy of adoptive cell transfer therapy (ACT) (isolating antigen-specific cells from the patient, expanding and activating these cells, and then re-administering the "boosted" cells back to the patient) and cancer vaccination therapy in cancer patients. )
Title: Approved Study #2: Genetic Predictors of Colon Cancer Recurrence
Approval Date: July 29, 2009
Principal Investigator: Phillip Buckhaults, Ph.D.
Details: The purpose of this study is to determine if genetic markers of positive lymph node involvement can predict recurrence among node-negative colon cancer patients.
Title: Examination of KLF4 Expression in Kidney and
Principal Investigator: Walden Ai, Ph.D.
Details: KLF4 is a protein involved in cell proliferation. The over expression of KLF4 has been reported in breast cancer and may play a role in cancer development.
The aim of this study is to examine KLF4 expression in kidney and breast cancers and to further examine the over expression of KLF4 may play in the development of these cancers.
This clinical trial is being offered at the following location:Lexington Medical Center